NEW YORK (GenomeWeb News) – Singapore-based VolitionRx today announced it has raised about $1.2 million, which will be used to support further development of its diagnostic test kits.

The firm, which is developing blood-based diagnostic tests for cancer using its nucleosomes technology, raised about $1 million through a private placement of 582,510 shares for $1.75 per share. Each share entitles the holder to one share of common stock and one warrant to purchase half a share of common stock at $2.60 per share, valid for four years.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: gene regulation changes linked to human brain evolution, and more.

The New York Stem Cell Foundation's Initiative on Women in Science and Engineering working group presents seven strategies to promote gender equality in the sciences.

Researchers link a genetic variation to the ability to quickly process arsenic in people living in the Andes Mountains.

A small portion of pregnant women who've undergone non-invasive prenatal testing have found out from the test that they have cancer.